Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

开始日期2016-11-01

申办/合作机构

SerenaGroup, Inc.

[+1]

NCT00792688 / Completed临床2期

Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

开始日期2008-10-01

申办/合作机构

TR Therapeutics, Inc.

NCT00656474 / Completed临床1/2期

Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

开始日期2008-03-01

申办/合作机构

TR Therapeutics, Inc.

100 项与 TR-987 相关的临床结果

登录后查看更多信息

100 项与 TR-987 相关的转化医学

登录后查看更多信息

100 项与 TR-987 相关的专利（医药）

登录后查看更多信息

项与 TR-987 相关的文献（医药）

2011-05-01·Wound Repair and Regeneration3区 · 医学

Particulate β‐glucan induces TNF‐α production in wound macrophages via a redox‐sensitive NF‐κβ‐dependent pathway

3区 · 医学

Article

作者: Savita Khanna ; Eric Collard ; Sashwati Roy ; Chandan K. Sen ; Urmila Gnyawali ; Gayle M. Gordillo ; Ryan Dickerson

ABSTRACTGlucans are known to promote wound repair. Noncellulosic β‐glucans are recognized as potent immunological activators. β‐Glucans are generally safe and are known to attenuate the rate of postoperative infection. Glyc101 is a particulate β‐glucan isolated from Saccharomyces cerevisiae. In this study, the hypothesis that Glyc101 regulates wound macrophage function was tested. Glyc101 induced tumor necrosis factor (TNF) α transcription in macrophages isolated from murine wound site. Multiplex assay identified interleukin (IL)‐10 and TNFα as two cytokines that are induced by Glyc101 in human blood monocyte‐derived macrophages. Glyc101‐induced TNFα production was observed to be mediated via the TLR‐2 and dectin‐1 receptors, receptor tyrosine kinases and NFκB activation. In murine wound macrophages, Glyc101 potentiated phorbol 12‐myristate 13‐acetate‐induced respiratory burst. In vivo, implantation of Glyc101‐enriched polyvinyl alcohol‐sponges at the wound‐site induced TNFα expression in macrophages. Consistently, Glyc101 induced TNFα expression in wound‐site macrophages isolated from two patients with chronic wounds. These observations establish the translational significance of the net findings of this study. Activation of wound macrophages by Glyc101 represents one of the potential mechanisms by which this β‐glucan may benefit chronic wounds where inefficient inflammatory response is one of the underlying causes of impaired healing.

100 项与 TR-987 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性静脉功能不全	临床2期	美国	TR Therapeutics, Inc.	2016-11-01
静脉曲张溃疡	临床2期	-	Kazia Therapeutics Ltd.	-
创伤和损伤	药物发现	美国	Glycotex, Inc.	2008-03-01
静脉曲张溃疡	药物发现	澳大利亚	TR Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	临床2期	慢性静脉功能不全	82	TR987® 0.1% gel	觸願蓋夢構壓鹹網鑰淵(鑰憲餘顧衊範遞製網襯) = 積築獵觸鬱糧選簾繭鑰醖淵齋糧網顧網膚鏇淵 (構壓蓋淵艱鏇窪憲遞築 ) 更多	积极	2023-07-03
				Placebo gel	觸願蓋夢構壓鹹網鑰淵(鑰憲餘顧衊範遞製網襯) = 獵範鹽鹹選築衊壓憲獵醖淵齋糧網顧網膚鏇淵 (構壓蓋淵艱鏇窪憲遞築 ) 更多
NCT00656474 (CTgov)	临床1/2期	创伤和损伤	12	GLYC-101 (GLYC-101 Active Retro-auricular Site (1 Per Participant))	築衊鹽齋夢構簾積積淵(鬱醖構蓋簾衊簾構選鏇) = 鬱鹽繭衊顧繭製鬱艱膚鬱構選衊壓築積鹹餘願 (製範膚選築觸衊繭壓構, 衊積膚壓鹽鹹壓獵積遞 ~ 簾衊襯顧網蓋襯範顧窪) 更多	-	2011-07-25
				Placebo (Placebo Retro-auricular Site (1 Per Participant))	築衊鹽齋夢構簾積積淵(鬱醖構蓋簾衊簾構選鏇) = 願遞選夢觸願窪艱蓋簾鬱構選衊壓築積鹹餘願 (製範膚選築觸衊繭壓構, 獵衊築願憲觸願廠糧襯 ~ 獵鏇選網顧願遞遞襯遞) 更多